Page 26 - புற்றுநோய் சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) Basel, Switzerland, July 29, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer. 1 Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity. Dr. Marc Engelhardt, Chief Medical Officer, commented: The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.

Basel stadtNils schrMarc engelhardtCancer researchHead of corporate communications investor relationsDrug administrationSwiss exchangeBasilea pharmaceutica ltdOrphan drug designationDrug designationChief medical officerBasilea pharmaceuticaCorporate communicationsClinical oncologyCancer therapeuticsMolecular biology